{"entity":{"id":"he-jie","kind":"person","name":"Jie He","aka":[],"tldr":"Runs China's national cancer centre and the registry that reports the country's cancer statistics.","summary":"Jie He is President of the Cancer Hospital of the Chinese Academy of Medical Sciences, Director of the National Cancer Center of China and a thoracic surgeon. He runs China's national cancer centre and the registry that reports the country's cancer statistics, overseeing the national cancer registry, screening programmes and clinical research infrastructure. His publications include the report on cancer incidence and mortality in China in 2022. His interests span thoracic surgery, lung and oesophageal cancer, cancer registry and statistics, and screening policy.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=He%20J%5BAuthor%5D%20National%20Cancer%20Center%20China%20cancer%20statistics"}],"tags":[],"related":[],"cancers":["nsclc","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital","ncc-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Cancer Hospital, Chinese Academy of Medical Sciences; Director, National Cancer Center of China; thoracic surgeon","institutionId":"cams-cancer-hospital","specialisms":["Thoracic surgery","Lung and oesophageal cancer","Cancer registry and statistics","Screening policy"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=He%20J%5BAuthor%5D%20National%20Cancer%20Center%20China%20cancer%20statistics"}],"papers":[{"title":"Cancer incidence and mortality in China, 2022","journal":"Journal of the National Cancer Center","year":2024,"doi":"10.1016/j.jncc.2024.01.006"},{"title":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071"}]},"route":"/people/he-jie/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"institution":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/"},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/"}],"paper":[{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/"}]}}